CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer

The Journal of Clinical Oncology has published the final results of the CALYPSO trial evaluating the combination of savolitinib, a MET inhibitor, with durvalumab, an anti-PD-L1 immune checkpoint inhibitor, in patients with metastatic papillary renal cell carcinoma. Papillary RCC is a rare and historically difficult-to-treat subtype of kidney cancer with limited approved targeted options, making novel combination strategies a high clinical priority. The rationale for this combination lies in the frequent MET pathway alterations found in papillary RCC paired with the demonstrated activity of checkpoint inhibitors across renal cell carcinoma subtypes. These definitive results from the named trial, published in a top-tier oncology journal, provide important efficacy and safety data that will help guide treatment decisions for this underserved patient population.